Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05124080
Other study ID # IRB-300008245
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date March 1, 2024
Est. completion date February 2027

Study information

Verified date March 2024
Source University of Alabama at Birmingham
Contact Ralee' Bunt, MSPH
Phone 205-502-9960
Email erikabunt@uabmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

. An open label proof of concept study will be conducted to assess the efficacy and safety of deucravactinib for treatment of nail psoriasis. Twenty adult patients with nail psorasis and skin disease qualifying for a systemic agent per investigator will be treated with deucravacitinib 6 mg daily. Subjects will be assessed for a total of 48 weeks. Psoriasis assessments such as the modified Nail Psoriasis Severity Index will be conducted. Photos will be used to document nail involvement. Descriptive statistical analysis will be conducted at the conclusion of the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date February 2027
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patients 18 and older - Give written informed consent prior to any study procedures being conducted, and candidates will authorize the release and use of protected health information (PHI) - Be willing and consent to having photos taken of their fingernails - Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions). - Diagnosis of chronic plaque psoriasis that has been present for at least 6 months prior to baseline - Plaque psoriasis qualifying for a systemic agent per investigator. - Nail psoriasis in at least one finger nail with a mNAPSI of 8 or greater or a total modified Nail Psoriasis Severity Index of 20 or greater - A Nail Pain NRS score of 3 or higher. The Nail Pain NRS will assess the severity of pain linked to the nail disease. - Must have discontinued all systemic therapies for the treatment of psoriasis or psoriatic arthritis at least 4 weeks or 5 half-lives, and biologics for at least 2 months or 5 half-lives (whichever is longer) prior to baseline visit - Must have discontinued all topical therapies for the treatment of psoriasis at least 2 weeks prior to baseline visit - Subjects must have discontinued UV therapy at least 2 weeks prior to baseline and PUVA at least 4 weeks prior to baseline. - Subjects must be in good general health without significant uncontrolled comorbidities, other than psoriasis, as determined by the investigator based on exam findings, medical history, and clinical laboratories. Patients with stable mild renal insufficiency are eligible for enrolling in this trial. - Females of childbearing potential must use an approved birth control method while receiving treatment and for 28 days following the last dose of deucravacitinib, and there must be a documented negative pregnancy tests prior to initiating treatment. Approved birth control methods include hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation (tying your tubes), partners vasectomy, or male or female condoms that are not made of natural materials PLUS a diaphragm with spermicide, cervical cap with spermicide, or a contraceptive sponge with spermicide. Females not of child bearing potential are defined as being at least 1 year postmenopausal or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy). - Male subjects, including those who have had a vasectomy, must use condoms not made of natural materials for the duration of the trial and for at least 28 days after the last dose of deucravacitinib if conception is possible. Exclusion Criteria: - Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled. - Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study. - Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years. - Pregnant or breast feeding. - Active substance abuse or a history of substance abuse within 6 months prior to Screening. - Malignancy or history of malignancy, except for: 1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas; 2. treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years. - Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer). - Prior treatment with deucravacitinib. - Unable to comply with the protocol (as defined by the Investigator; i.e. drug or alcohol abuse or history of noncompliance). - Concomitant therapy with medications that are strong cytochrome P450 inducers, including rifampin, phenobarbital, carbamazepine, or phenytoin. - Any other dermatologic conditions that prohibit or confound the ability of the investigator to interpret skin and/or nail exam findings. - Patients who will be unable to avoid the use of systemic steroids, excluding intranasal or inhaled steroids that will be permitted, for the duration of the trial. - Any known hypersensitivity to deucravacitinib. - Prisoners or subjects who are involuntarily incarcerated - Subjects who are compulsorily detained for treatment of either psychiatric or physical illness - Inability to comply with restrictions and prohibited activities listed in study protocol - Site personnel or their immediate family

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deucravacitinib
All participants will receive 6 mg of Deucravacitinib daily.

Locations

Country Name City State
United States University of Alabama at Birmingham - Department of Dermatology Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the modified Nail Psoriasis Severity Index (mNAPSI) compared to baseline Mean percent change of mNAPSI baseline to week 24
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03209388 - Study of the Efficacy and Safety of Topical P-3073 in the Treatment of Mild to Moderate Psoriatic Fingernail/s Phase 3
Completed NCT00999687 - Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails Phase 2/Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Completed NCT04580537 - Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails Phase 2
Not yet recruiting NCT03263624 - Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease Phase 4
Completed NCT02606760 - Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis Phase 3
Completed NCT04227288 - A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis Phase 4
Withdrawn NCT03079973 - Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s Phase 3
Completed NCT04380597 - Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
Completed NCT03991936 - Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis Phase 4
Completed NCT03757364 - Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis
Completed NCT02016482 - A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis Phase 3
Completed NCT02168933 - 308nm Excimer Laser for Treatment of Fingernail Psoriasis N/A
Completed NCT01445886 - Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis Phase 2/Phase 3
Not yet recruiting NCT05695833 - Nd:YAG Laser and Radiofrequency in Treatment of Fingernail Psoriasis N/A
Completed NCT03616561 - Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)
Completed NCT02235480 - Efficacy and Safety of Tazarotene Gel in Nail Psoriasis Phase 2
Not yet recruiting NCT06150794 - Methotrexate Alone vs Combination With Excimer Light in Nail Psoriasis N/A
Completed NCT03946826 - A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser (PDL) in the Treatment of Nail Psoriasis N/A
Active, not recruiting NCT05072886 - Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis Phase 1